Editas Medicine (EDIT): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Editas (EDIT)

The market price visualization for Editas Medicine, Inc. (EDIT), whose EV/EBITDA metric is recorded at 0.00, demonstrates the potential of this pioneer in CRISPR-based oncology and ophthalmology therapies. Ownership of key patents enables the creation of ultra-precise blood correction drugs, ensuring leadership in genetics. Despite a current lack of pricing power due to the R&D stage, future high-cost treatment courses may face government regulation.

EDIT (Editas) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/17/2026

EDIT (Editas Medicine): analytical breakdowns and indicator data

- current price and projected stock value:
- stock exchange capitalization data:
Fundamental company valuation:editasmedicine.com EDIT
Product sample of editasmedicine.com

Editas Medicine, Inc. (EDIT) is developing capital-intensive CRISPR technologies for the radical treatment of genetic pathologies. This metric compares the total enterprise value of the business with its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA trend, an investor assesses real market volatility and debt management efficiency. For this scientific pioneer, this indicator serves as a measure of capital stability amidst high R&D expenditures.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Enterprise Value to EBITDA Ratio|KRRO: Enterprise Value to Operating Income Before Depreciation|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc